There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .
Role of perioperative intravenous iron therapy in elderly hip fracture patients: a single-center randomized controlled trial.
BACKGROUND The main objective of this study was to determine the efficacy of intravenous ( IV ) iron sucrose therapy reducing transfusion requirements in elderly patients undergoing hip fracture surgery . STUDY DESIGN AND METHODS This study was a prospect i ve r and omized controlled trial involving 200 patients undergoing hip fracture surgery . Group A ( 100 patients ) received st and ard treatment , while Group B ( 100 patients ) received iron sucrose ( 600 mg IV ) . The primary endpoint was the number of patients that were transfused postoperatively . The secondary endpoints were the rate of red blood cell units used , hematimetric variables of blood tests , mortality , infection rates , length of hospital stay , and appearance of side effects . RESULTS Differences in the percentage of patients requiring transfusion ( Group A 41.3 % vs. Group B 33.3 % ) and in the number of concentrates transfused ( 0.87±1.21 for Group A vs. 0.76±1.16 for Group B ) were not significant for the patient group as a whole , but were significant for patients with intracapsular fractures ( 45.7 % required transfusion in Group A vs. 14.3 % in Group B ; p<0.005 ) and in patients with a baseline hemoglobin ( Hb ) level of 12 g/dL or more ( 35.2 % required transfusions in Group A vs. 19 % in Group B ; p<0.05 ) . CONCLUSIONS Transfusion requirements in patients with intracapsular fracture or baseline Hb level of 12 g/dL or more appear to be reduced by IV iron sucrose therapy , but there was no difference in morbidity , mortality , or length of hospital stay . The treatment is safe and hastens recovery from blood loss
There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .